HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx: Challenging the Cox-2s?

Executive Summary

Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.

You may also be interested in...



NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?

NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?

hemoCORM Ltd.

The founders of European start-ups hemoCORM Ltd. and Alfama are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.

Alfama

The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel